Joseph Ronald Catapano, serving as the Chief Accounting Officer for Teladoc Health, Inc. (NASDAQ:TDOC), completed a sale of 653 shares of the company's common stock on July 2, 2026. The transaction resulted in a total value of $5,942, with the shares sold at a price of $9.10 per share. This divestment was executed specifically to satisfy tax withholding obligations associated with the vesting of Mr. Catapano's restricted stock unit (RSU) awards.
The sale follows the conversion of 2,083 restricted stock units into common stock on July 1, 2026. These units, which convert on a one-for-one basis, were part of a grant of 25,000 RSUs awarded to Mr. Catapano on October 1, 2024. The vesting schedule for these units dictates that one-third vests on the first anniversary of the grant date, with the remaining balance vesting in eight substantially equal quarterly installments thereafter.
Following these transactions, Mr. Catapano's direct holdings include 12,267 shares of Teladoc Health common stock and 10,418 restricted stock units. The transaction occurs as Teladoc shares trade near their 52-week high of $9.77. The stock has posted a 31% gain year-to-date. Valuation metrics from InvestingPro analysis indicate the stock appears undervalued at current levels, with a Fair Value estimate of $12.68.
In parallel operational developments, Teladoc Health has announced that its virtual care services are now accessible through Walmart's Better Care Services platform. This collaboration enables Walmart customers to utilize Teladoc's virtual urgent care, dermatology, and nutrition services. These services are available for both insured patients and cash-pay customers at a rate of $89 per visit.
Further expanding its clinical focus, BetterHelp, a component of Teladoc Health, has joined the Institute of Patient Safety and Quality of Virtual Care. This membership underscores the company's emphasis on clinical quality and continuous improvement in virtual care delivery.
Market analyst activity also reflects recent performance. Jefferies has raised its price target for Teladoc Health to $6.00 from $5.20, maintaining a Hold rating. This adjustment follows a strong first-quarter performance. The company's Integrated Care segment demonstrated positive revenue growth, while BetterHelp made significant progress in expanding its insured patients' revenue base.
Options trading activity for Teladoc Health reached 27,861 contracts. A significant portion of this activity involved the July 10, 2026, $10 call option. The stock closed at $9.29, representing a gain of $0.09 or 0.98%. After-hours trading saw the stock at $9.31, up $0.02 or 0.22%.